[Anti-TNF-alpha therapy in ulcerative colitis].
The most important factors that determine treatment strategy in ulcerative colitis (UC) are disease extent and severity. Orally-topically administered 5-aminosalicylates (5-ASA) remain the treatment of choice in mild-to-moderate UC. In contrast, the treatment of refractory (to steroids, azathioprine or 5-ASA) and fulminant cases is still demanding. New evidence supports a role for infliximab induction and/or maintenance therapy in these subgroup of patients leading to increased remission and decreased colectomy rates. The aim of this paper is to review the rationale for the use of TNF-alpha inhibitors in the treatment of UC.
Lakatos
Péter László
PL
Semmelweis Egyetem, Altalános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. u. 2/A 1083. kislakpet@bel1.sote.hu
Lakatos
László
L
D000208:Acute Disease; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D011788:Quality of Life; D012074:Remission Induction; D013256:Steroids / Q000008:administration & dosage / Q000009:adverse effects; D019966:Substance-Related Disorders; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab